Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 3
2003 1
2004 2
2005 1
2006 2
2007 7
2008 5
2009 3
2010 4
2011 5
2012 5
2013 2
2014 6
2015 2
2016 3
2017 6
2018 6
2019 11
2020 2
2021 8
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Patient-centric Comparability Assessment of Biopharmaceuticals.
Blümel M, Cordoba-Rodriguez R, Carroll JA, Beardsley RL, Maggio F, Wylie D, Tsang V, Ehrick R, Francq BG, Pohl T, Taktak S, Spasoff A, Morrison A, Albarghouthi M. Blümel M, et al. Among authors: pohl t. J Pharm Sci. 2024 Feb 17:S0022-3549(24)00053-4. doi: 10.1016/j.xphs.2024.02.010. Online ahead of print. J Pharm Sci. 2024. PMID: 38373591 Review.
Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory.
Gervais A, Dirksen EHC, Pohl T, Bechtold-Peters K, Burkitt W, D'Alessio V, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L. Gervais A, et al. Among authors: pohl t. Eur J Pharm Biopharm. 2023 Oct;191:57-67. doi: 10.1016/j.ejpb.2023.08.008. Epub 2023 Aug 13. Eur J Pharm Biopharm. 2023. PMID: 37582411 Free article.
Technical considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory.
Pohl T, Gervais A, Dirksen EHC, D'Alessio V, Bechtold-Peters K, Burkitt W, Cao L, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L. Pohl T, et al. Eur J Pharm Biopharm. 2023 Jul;188:231-242. doi: 10.1016/j.ejpb.2023.04.024. Epub 2023 May 3. Eur J Pharm Biopharm. 2023. PMID: 37146738 Free article.
An Intra-Company Analysis of Inherent Particles in Biologicals Shapes the Protein Particle Mitigation Strategy Across Development Stages.
Morar-Mitrica S, Pohl T, Theisen D, Boll B, Bechtold-Peters K, Schipflinger R, Beyer B, Zierow S, Kammüller M, Pribil A, Schmelzer B, Boehm S, Goetti M, Serno T. Morar-Mitrica S, et al. Among authors: pohl t. J Pharm Sci. 2023 May;112(5):1476-1484. doi: 10.1016/j.xphs.2023.01.023. Epub 2023 Jan 31. J Pharm Sci. 2023. PMID: 36731778
Deterministic Photon Sorting in Waveguide QED Systems.
Yang F, Lund MM, Pohl T, Lodahl P, Mølmer K. Yang F, et al. Among authors: pohl t. Phys Rev Lett. 2022 May 27;128(21):213603. doi: 10.1103/PhysRevLett.128.213603. Phys Rev Lett. 2022. PMID: 35687472
Rydberg exciton-polaritons in a Cu2O microcavity.
Orfanakis K, Rajendran SK, Walther V, Volz T, Pohl T, Ohadi H. Orfanakis K, et al. Among authors: pohl t. Nat Mater. 2022 Jul;21(7):767-772. doi: 10.1038/s41563-022-01230-4. Epub 2022 Apr 14. Nat Mater. 2022. PMID: 35422507
83 results